Fig. 1: Cumulative incidence and cytopenia associated with therapy-related myeloid neoplasm (t-MN) development in non-Hodgkin Lymphoma patients undergoing chimeric antigen receptor (CAR)-T therapy. | Blood Cancer Journal

Fig. 1: Cumulative incidence and cytopenia associated with therapy-related myeloid neoplasm (t-MN) development in non-Hodgkin Lymphoma patients undergoing chimeric antigen receptor (CAR)-T therapy.

From: Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma

Fig. 1

A Cumulative incidence of t-MN in NHL patients undergoing CAR T cell therapy at 2 years. B Complete blood count at day +30 post CAR T-cell therapy, day +100 post-CAR T-cell therapy, and at t-MN diagnosis. Hemoglobin in g/dL, platelets ×109/L, white blood cell count (WBC)—×109/L, and absolute neutrophil count (ANC)—×109/L.

Back to article page